Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences

Diabetes Care. 2005 Mar;28(3):757-8. doi: 10.2337/diacare.28.3.757.
No abstract available

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Letter

MeSH terms

  • Adult
  • Aged
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use*
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Benzimidazoles / therapeutic use*
  • Benzoates / therapeutic use*
  • Biphenyl Compounds
  • Blood Pressure / drug effects
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetic Angiopathies / drug therapy*
  • Female
  • Humans
  • Hypertension / drug therapy*
  • Male
  • Middle Aged
  • Telmisartan
  • Tetrazoles / therapeutic use*
  • Valine / analogs & derivatives*
  • Valine / therapeutic use*
  • Valsartan

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Benzimidazoles
  • Benzoates
  • Biphenyl Compounds
  • Tetrazoles
  • Valsartan
  • Valine
  • candesartan
  • Telmisartan